Department of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, China.
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, China.
Front Immunol. 2022 Jul 14;13:871661. doi: 10.3389/fimmu.2022.871661. eCollection 2022.
Different from surgery, chemical therapy, radio-therapy and target therapy, Chimeric antigen receptor-modified T (CAR-T) cells, a novel adoptive immunotherapy strategy, have been used successfully against both hematological tumors and solid tumors. Although several problems have reduced engineered CAR-T cell therapeutic outcomes in clinical trials for the treatment of thoracic malignancies, including the lack of specific antigens, an immunosuppressive tumor microenvironment, a low level of CAR-T cell infiltration into tumor tissues, off-target toxicity, and other safety issues, CAR-T cell treatment is still full of bright future. In this review, we outline the basic structure and characteristics of CAR-T cells among different period, summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for thoracic malignancies, and point out the current challenges and new strategies, aiming to provide new ideas and approaches for preclinical experiments and clinical trials of CAR-T cell therapy for thoracic malignancies.
不同于手术、化学疗法、放射疗法和靶向疗法，嵌合抗原受体修饰的 T 细胞（CAR-T）作为一种新型的过继免疫疗法，已成功用于治疗血液系统肿瘤和实体瘤。尽管在针对胸内恶性肿瘤的临床试验中，一些问题降低了工程 CAR-T 细胞治疗的效果，包括缺乏特异性抗原、免疫抑制性肿瘤微环境、CAR-T 细胞浸润肿瘤组织水平低、脱靶毒性和其他安全问题，但 CAR-T 细胞治疗仍然充满了光明的前景。在这篇综述中，我们概述了不同时期 CAR-T 细胞的基本结构和特征，总结了胸内恶性肿瘤 CAR-T 细胞治疗临床试验中常见的肿瘤相关抗原，并指出了目前的挑战和新策略，旨在为胸内恶性肿瘤 CAR-T 细胞治疗的临床前实验和临床试验提供新的思路和方法。
